Aim-To evaluate the clinical usefulness of the thyrotropin releasing hormone (TRH) test and estimation of thyroid autoantibody concentrations in patients with borderline raised thyroid stimulating hormone (TSH). Methods-The records of 34 consecutive patients with persistent borderline increased TSH (4.4-9.9 mU/l) referred to the Medical Investigation Unit were reviewed. 
Subclinical hypothyroidism, a condition in which clinically euthyroid patients have borderline raised serum thyroid stimulating hormone (TSH 4 3-9 9 mU/1) and a normal thyroxine concentration on at least two occasions, often causes diagnostic and management problems. Although the condition has been recognised for over 25 years,1 little is known about its course and there is no consensus on the management of these patients. A borderline raised TSH concentration and the presence of thyroid autoantibodies are biochemical features used to identify people at risk of progression to overt hypothyroidism.2 It has been suggested that those with raised TSH concentrations and positive thyroid microsomal antibodies may be treated with thyroxine whilst for those without antibodies the raised TSH concentrations should be disregarded. 3 Performance ofthe thyrotropin releasing hormone (TRH) test is often used as an additional test in these patients. 45 The availability of sensitive and ultrasensitive assays for TSH and much improved assays for free thyroid hormones have limited the indications for the performance ofthe TRH test, especially in patients with suspected thyroid disease. This study reviews the contribution of the TRH test and thyroid antibodies to the management of patients with suspected subclinical hypothyroidism referred to a Medical Investigation Unit over an 18 month period.
Methods
The records of 34 (30 women and four men) consecutive patients referred over an 18 month period were reviewed. The patients were aged between 23 and 80 years (58+13-9 SEM). All of the patients had borderline raised TSH concentrations (4 4-9-9 mU/l) on at least two occasions three to six months apart.
Total thyroxine was measured by radioimmunoassay (Immunodiagnostic Systems Ltd, Tyne and Wear, UK); TSH was measured using a coated tube immunoradiometric assay (Immunodiagnostic Systems Ltd). Interassay precision (coefficient of variation) for the TSH assay was 7% at 3 9 mU/l and 6% at 26-5 mU/l. Thyroglobulin antibodies and thyroid microsomal antibodies were assessed by passive haemagglutination using Serodia kits (Fujirebio Inc., Tokyo, Japan). The TRH test was performed by intravenous administration of200 ,ug TRH and blood samples were collected at zero, 20 and 60 minutes.
The indices used in the diagnosis of hypothyroidism were increment of TSH >30 mU/l, 20 minute TSH >35 mU/l or a proportional rise (20 minute TSH/basal TSH >6).
Results
Administration of TRH was well tolerated by all of the patients and no side effects were reported. The mean total thyroxine concentration in the patients was 92+ 2-7 (SEM) nmol/l (range 
